Mission Update

Community Summit

February 21, 2026

Anders Carlson

Breakthrough T1D™

Formerly JDRF

Our Mission

To accelerate life-changing breakthroughs to cure, prevent, and better treat type 1 diabetes and its complications.

Breakthrough T1D™
Formerly JDRF

We are the premier T1D organization working at every step of the pipeline

We are *accelerators*

Breakthrough T1D™ Formerly JDRF

20+ years of progress and counting



Breakthrough T1D™ Formerly JDRF

Today’s focus: Updates from our research priority areas



Breakthrough T1D™
Formerly JDRF

Why is early detection important?



- Reduce risk for diabetic ketoacidosis at diagnosis
- Intervene with an approved therapy
- Participate in clinical trials
- Time to prepare

Breakthrough T1D™
Formerly JDRF

General population screening for T1D is coming

The challenge:
New T1D diagnoses are rising globally

The solution:
General population screening for T1D, starting at a young age

Breakthrough T1D's role
Upcoming publication by experts in the field to help guide clinicians on integrating general population T1D screening into their clinical practice

Breakthrough T1D™ Formerly JDRF

Disease-modifying therapies: Changing the trajectory of T1D

Disease-modifying therapies have the potential to **change the trajectory of T1D** by:

- Slowing or halting its progression
- Reversing its course
- Preventing it from ever occurring

The goal:

Preserve and/or increase the body's healthy, insulin-producing beta cells.

Breakthrough T1D™ Formerly JDRF

Disease-modifying therapies TODAY

Several disease-modifying therapies are in Breakthrough T1D-supported clinical trials around the world.

Tzield is the first approved disease-modifying therapy for T1D, and Breakthrough T1D will make sure it's not the last.

Breakthrough T1D™
Formerly JDRF

One step closer to Tzield for young kids

In the U.S., Tzield is approved for **people ages 8+** with pre-symptomatic (stage 2) T1D.

It has the potential to delay symptomatic (stage 3) T1D, and the need for insulin therapy, by an average of 3 years.

What it is

- The PETITE-T1D clinical trial is evaluating the safety of Tzield in kids ages 1-7 with pre-symptomatic T1D.
- No new safety issues have been identified so far.

Why it matters

- Tzield is under **priority review by the FDA** for this population.
- *Human impact:* If approved, this would give families the opportunity to delay the onset of symptomatic T1D in their young children.

Our role

- Breakthrough T1D helped guide Tzield through the pipeline at every step of the way, and we support widespread screening to identify people with pre-symptomatic T1D who may benefit from Tzield.

Breakthrough T1D™ Formerly JDRF

Unlocking cures through cell replacement therapies



Cell therapies **replace destroyed beta cells** with functional, insulin-producing cells.

The goal:

Restore the body's ability to produce insulin.

Thanks to years of Breakthrough T1D leadership and investment, several cell therapies are in human clinical trials—**and people are becoming insulin independent.**

Breakthrough T1D™ Formerly JDRF

Project Accelerate Cell Therapy (ACT)

Project ACT is a Breakthrough T1D initiative to dramatically speed cell therapy products as T1D cures through coordinated efforts to simultaneously advance research, development, regulatory, access, and adoption.

https://www.breakthrought1d.org/project-act/

Breakthrough T1D™ Formerly JDRF

Vertex's zimislecel (VX-880) keeps hitting milestones

- **What it is:** one-year update on phase 1/2 trial for manufactured islet therapy that requires immunosuppression
- **All 12 participants reached the primary endpoint** (elimination of severe hypoglycemic events and HbA1c<7%)
- Phase 3 has completed enrollment, but as of November 2025 there is a temporary postponement of dosing pending an internal manufacturing analysis
- **Our role:** years of support spanning over two decades from Breakthrough T1D and the T1D Fund



10/12

participants are insulin independent

Breakthrough T1D™ Formerly JDRF

T1D Fund A Breakthrough T1D Venture™

VERTEX

Sana Biotechnology's gene-edited cells evading the immune system for 6+ months

- One individual with T1D received deceased donor islets gene-edited with Sana's Hypoimmune (HIP) technology.
- This therapy **does not require the use of immunosuppressives.**
- After 6 months, **the cells are still alive and making insulin.**

Our role: The T1D Fund has invested in Sana and we continue to work closely with them.

T1D Fund
A Breakthrough T1D Venture™

Sana Biotechnology

Breakthrough T1D™ Formerly JDRF

A few notable cell therapies in the pipeline

Therapy	Company	Manufactured or donor-derived?	Immune suppression required?	Phase 1	Phase 2	Phase 3
VX-880 (Zimislecel)	VERTEX	Manufactured	✓	→	→	→
Tegoprubart	Eledon Pharmaceuticals	Donor-derived	✓	→	→	
Cell Pouch	SERNOVA	Donor-derived	✓	→	→	
UP421	Sana Biotechnology	Donor-derived		→		
OZTx-410	ORIZURU THERAPEUTICS	Manufactured	✓	→		

How we are improving lives

Improving Lives

Devices: AID systems and components

Therapies for complications

Therapies for glucose and weight control: insulins and non-insulin therapies

Behavioral therapies for psychosocial burden

Breakthrough T1D™ Formerly JDRF

Breakthrough T1D has improved lives already and is driving the field toward a better future

Breakthrough T1D spearheaded the development of automated insulin delivery (AID) systems, and we're supporting research into closing the loop.

We're funding multiple trials to test GLP-1s and SGLT inhibitors in managing weight and glucose in people with T1D.

We've transformed therapies for eye disease and are supporting treatments to address heart and kidney complications.

We are ensuring that people with T1D get the mental and emotional support they need.

The Next Generation of Automated Insulin Delivery

Goal:

AID systems with no need for manual input from the user

Breakthrough T1D's years-long efforts drove the development of the first AID system.

Now, we're working on closing the loop—and making sure everyone who wants an AID can get one.

Breakthrough T1D™
Formerly JDRF



Updates on Continuous Ketone Monitoring (CKM)

- **CKM has substantial benefits for the T1D community**
- Five new NIDDK-funded studies will develop CKM for safe and effective use of SGLT inhibitors in T1D
- Tandem, Beta Bionics, Sequel MedTech, and Ypsomed will integrate Abbott's dual glucose ketone sensor into their AID systems

Breakthrough T1D™
Formerly JDRF

Clinical trials: The key to cures

Breakthrough T1D™
Formerly JDRF

Clinical trials are the way forward

The challenge:
Lack of clinical trial participation makes trials take longer and cost more money. It's especially difficult to recruit newly diagnosed people.

The solution:
Widespread education and recruitment!

www.breakthrought1d.org/clinical-trials

Breakthrough T1D™
Formerly JDRF

- More than **40 years of experience** in cutting-edge diabetes research
- Integrating new research findings into clinical practice and discovering innovative ways to use technology to **improve diabetes care**
- Patients have one-on-one time with nurses, dietitians and MDs as part of their research visits.


Why
Participate?



Help us answer important questions by referring your patients to diabetes research studies!

*** New insulin pumps for T1 DM***

*** Insulin pumps for T2 DM ***

*** GLP-1 comparison studies***

*** Once-weekly insulin ***

*** CGM & CKM Studies ***

To learn more about studies at IDC:

https://www.healthpartners.com/institute/research/studies/category/diabetes/

Register to Be Contacted for Future Studies?

www.ResearchHP.com

HealthPartners Institute

Completing this form does not automatically enroll or obligate you to participate in research. All information entered in the form is confidential and secure.

Advocacy and Medical Affairs

Advocacy is key to our mission

Breakthrough T1D's Advocacy works at every step of the pipeline to drive our mission forward.

Engage with policymakers

Amplify our mission

Accelerate therapy development

Facilitate access in the U.S. and globally

Advocacy win: Continued renewal of the Special Diabetes Program (SDP).

Breakthrough T1D™ Formerly JDRF

Medical affairs drives clinical adoption of breakthroughs

Breakthrough T1D's Medical Affairs helps bring new T1D therapies, treatments, and devices into clinics.

Change the T1D care model

Educate healthcare professionals (HCP)

Provide resources for the community and medical teams

Accelerate clinical adoption

Medical Affairs win: Launch of accredited HCP resources to educate clinicians on new therapies, devices, and trials.

Breakthrough T1D™ Formerly JDRF

What to look forward to

What's next?

#1 – Continuous Ketone Monitoring

#2 – GLP-1 and Other Dual Agonist Therapies

#3 – Fully Closed Loop Systems

#4 – Early Intervention Therapies

None of this would be possible without you. THANK YOU!

Breakthrough T1D™
Formerly JDRF